arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Fortress Biotech, Inc.

FBIO
$2.69 ▼ -0.09 (-3.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
21 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Fortress Biotech, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $75.1M
Dividend Yield
Revenue Growth 9.7%
Op. Margin -111.0%
ROIC -67.4%
FCF / Share $-2.36
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity 1.05
info Valuation on last close. End-of-day price, Aug 7, 2026.

21-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$63.26M
↑ +9.7%
Net Income Profit after all expenses
$6.82M
↑ +114.8%
Operating Margin Operating profit as % of sales
-111.0%
↑ +42.0% 2th
FCF / Share Free cash flow per share
$-2.36
↑ +38.9%
Long-Term Debt Long-term obligations
$52.42M
↓ -9.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
24
Returns
78
Financial Health
31
Cash Quality
2

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 21 years · 74 quarters